(Q61455444)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

title

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

0 references

0 references

0 references

0 references

0 references

hepatocellular carcinoma

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

Hidenori Toyoda

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

2

Takashi Kumada

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

14

Toshifumi Tada

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

9

Masashi Hirooka

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

12

Toru Ishikawa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

4

Koichi Takaguchi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

8

Kazuto Tajiri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

10

Noritomo Shimada

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

13

Hironori Ochi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

17

Akemi Tsutsui

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

18

Norio Itokawa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

22

Kojiro Michitaka

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

3

Kazuya Kariyama

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

19

Michitaka Imai

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

5

Masanori Atsukawa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

16

Kazuhiro Nouso

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

21

Yoichi Hiasa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

20

Kouji Joko

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

15 April 2020

23

object named as

Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

author name string

Ei Itobayashi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

Kunihiko Tsuji

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

Hiroshi Shibata

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

language of work or name

English

0 references

publication date

21 December 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

page(s)

137-146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

Transection of the oesophagus for bleeding oesophageal varices

15 April 2020

cites work

1 reference

12 December 2020

Management of hepatocellular carcinoma

1 reference

12 December 2020

Sorafenib in advanced hepatocellular carcinoma

1 reference

12 December 2020

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

12 December 2020

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

12 December 2020

Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis

1 reference

12 December 2020

New contrast enhanced ultrasonography agent: impact of Sonazoid on radiofrequency ablation

1 reference

12 December 2020

Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging.

1 reference

12 December 2020

Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.

1 reference

12 December 2020

Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid

1 reference

12 December 2020

Investigation of the freely available easy-to-use software 'EZR' for medical statistics

1 reference

12 December 2020

Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index

1 reference

12 December 2020

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

1 reference

12 December 2020

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

1 reference

12 December 2020

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

1 reference

12 December 2020

Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade

1 reference

12 December 2020

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

1 reference

12 December 2020

Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation

1 reference

12 December 2020

General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan

1 reference

12 December 2020

Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma

1 reference

12 December 2020

Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease

1 reference

12 December 2020

Sarcopenia and two types of presarcopenia in Japanese patients with chronic liver disease

1 reference

12 December 2020

Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib.

1 reference

12 December 2020

Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma

1 reference

12 December 2020

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

12 December 2020

Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications

1 reference

12 December 2020

Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.

1 reference

12 December 2020

Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.

1 reference

12 December 2020

Muscle volume loss a prognostic factor for death in liver cirrhosis patients and special relationship to portal hypertension.

1 reference

12 December 2020

Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis

1 reference

12 December 2020

Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma.

1 reference

12 December 2020

Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function.

1 reference

12 December 2020

Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study

1 reference

12 December 2020

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

1 reference

12 December 2020

Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

1 reference

12 December 2020

Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice

1 reference

12 December 2020

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

1 reference

12 December 2020

Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment

1 reference

12 December 2020

Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy

1 reference

12 December 2020

Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis

1 reference

12 December 2020

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1002/CAM4.1909

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30575325%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

PubMed publication ID

30575325

1 reference